Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

5 Bargain Breakout Stocks Offering Stunning Returns

Published 08/23/2017, 09:35 PM
Updated 07/09/2023, 06:31 AM

Picking breakout stocks is probably one of the most popular techniques that active investors utilize. The key to this kind of stock selection is to identify those that are trading within a narrow band. Such stocks are to be acquired as soon as they move above this channel and are sold when they fall below. In case a stock moves above this band, it normally gains momentum.

Spotting Prospective Candidates

In order to identify breakout stocks, you must first determine their resistance and support levels. A resistance level is the barrier which must be broken so as to be identified as a breakout stock. Meanwhile, a support level is the floor for the stock’s movement.

At the breakout level, demand for the stock has peaked, making it a natural choice for traders. On the other hand, when a stock hits the support floor, traders are eager to offload it. In order to spot breakout stocks, you would have to see which of these are on the brink of breaking the resistance barrier or those that have just breached this level.

Has a Breakout Really Occurred?

The primary risk associated with such a strategy is that the decision to buy an apparent breakout candidate has been incorrectly timed. When a stock moves above the resistance level, it should be a highly prized commodity for traders. However, whether such a breakout is at all genuine is another matter altogether.

For a bona fide breakout, the stock’s earlier resistance barrier should become its new support level. This only happens if the trading channel that has been established is tested by observing long-term price trends. The strength of the support and resistance levels can be ascertained only through such a study. Despite the risk of misidentification, correctly identifying such stocks can yield considerable returns, even at a price which may not seem attractive at first glance.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Screening Parameters

Percentage price change over four weeks between 10% and 20% (Stocks which are showing considerable price increases, but whose gains are not excessive.)

Current Price /52-Week High greater than or equal to 0.9 (Stocks that are trading 90% close to their 52-week highs.)

Zacks Rank less than or equal to #2
(Only Strong Buy and Buy rated stocks can get through.)

Beta for 60 months less than or equal to 2
(Stocks which move by a greater degree than the broader market but within a reasonable limit.)

Current price less than or equal to $20 (Stocks which are reasonably priced.)

These criteria narrow down the universe of over 7867 stocks to only 10.

Here are the top five stocks that meet these criteria:

Summer Infant, Inc. (NASDAQ:SUMR) is a designer, marketer and distributor of branded durable juvenile health, safety and wellness products, which are sold principally to large U.S. retailers. The company's expected earnings growth for the current year is more than 100%. Summer Infant has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Intra-Cellular Therapies has a Zacks Rank #2 (Buy) and its expected earnings growth for the current year is 12.9%.

PDL BioPharma (NASDAQ:PDLI) pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL BioPharma has a Zacks Rank #2 and its expected earnings growth for the current year is more than 100%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Cogentix Medical, Inc. (NASDAQ:CGNT) is a designer, developer, manufacturer and marketer of video endoscopy and fiberoptic products. Cogentix Medical has a Zacks Rank #2 and its expected earnings growth for the current year is 88.9%.

Intrepid Potash, Inc. (NYSE:IPI) is the largest producer of potash in the U.S. and is dedicated to the production and marketing of potash and langbeinite. Intrepid Potash has a Zacks Rank #2 and its expected earnings growth for the current year is 67.1%.

You can get the rest of the stocks meeting these criteria by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and backtest them first before taking the investment plunge.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance.

Zacks Restaurant Recommendations: In addition to dining at these special places, you can feast on their stock shares. A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector. Download it free »



Intrepid Potash, Inc (IPI): Free Stock Analysis Report

Cogentix Medical, Inc. (CGNT): Free Stock Analysis Report

PDL BioPharma, Inc. (PDLI): Free Stock Analysis Report

Intra-Cellular Therapies Inc. (ITCI): Free Stock Analysis Report

Summer Infant, Inc. (SUMR): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.